Sunshine Biopharma, Inc.  

(Public, OTCMKTS:SBFM)   Watch this stock  
Find more results for OTC:SBFM
0.00791
0.00000 (0.00%)
Jul 26 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.04
Open     -
Vol / Avg. 0.00/667,701.00
Mkt cap 2.10M
P/E     -
Div/yield     -
EPS -0.01
Shares 268.88M
Beta 34.23
Inst. own     -

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -96661.41%
Operating margin - -79264.33%
EBITD margin - -37760.23%
Return on average assets -162.85% -404.79%
Return on average equity - -
Employees 3 -
CDP Score - -

Address

469 Jean-Talon West, 3rd Floor
MONTREAL, QC H3N 1R4
Canada
+1-514-7649698 (Phone)
+1-514-7649699 (Fax)

Website links

Description

Sunshine Biopharma, Inc. is a pharmaceutical company. The Company focuses on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound is Adva-27a, which is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. The Company's Adva-27a is a Topoisomerase II inhibitor. Adva-27a is used against various multidrug resistant cancer cells: Breast Cancer Cells (MCF-7/MDR), Small Cell Lung Cancer Cells (H69AR), Uterine Cancer (MES-SA/Dx5) and Pancreatic Cancer (Panc-1). Adva-27a has a clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats. The Company is focuses on conducting Phase I clinical trials for Adva-27a.

Officers and directors

Steve N. Slilaty Chairman of the Board, President, Chief Executive Officer
Age: 62
Camille Sebaaly Chief Financial Officer, Secretary, Director
Age: 54
Abderrazzak Merzouki Chief Operating Officer, Director
Age: 51